OR WAIT null SECS
© 2023 MJH Life Sciences™ and BioPharm International. All rights reserved.
The Birtley, UK facility added cleanroom, manufacturing, and testing facilities for biopharma manufacturing single-use systems.
Parker Bioscience Filtration, which supplies automated single-use solutions that include filtration, single-use fluid-handling systems, and sensors, opened expanded facilities at its Birtley, United Kingdom site, including new cleanroom, manufacturing, and testing facilities, the company announced in a Aug. 15, 2019 press release. The SciLog Suite supports process development by providing a facility to test and optimize unit operations within a production process. The facility includes the SciLog FD for bulk drug filtration and dispense, the SciLog TFF for tangential flow filtration operations, and the SciLog NFF for normal flow filtration operations. The facility can accommodate more than 20 people.
Earlier this year, as part of the same investment program, the company announced the opening of a new cleanroom facility at the site that is dedicated to the manufacture of single-use assemblies.
“It’s hugely exciting to have opened the doors to our extended and refurbished site in Birtley. The investment in these facilities demonstrates Parker Hannifin’s commitment to our European customer base and through this, we have strengthened the level of technical support and service that we can offer across biopharmaceutical manufacturing.We have shortened the supply chain for our European customers and made it easier for customers to access filtration solutions and automated systems,” said Kris Holmes, general manager of Parker Bioscience Filtration, in the press release. “In addition, we have also provided a greatly enhanced working environment for Parker Bioscience Filtration’s specialist workforce. The overall investment in our laboratory, cleanroom, manufacturing, office, and warehouse facilities has made our Birtley premises one of the most modern manufacturing sites for integrated bioprocessing solutions in EMEA.”